<DOC>
	<DOCNO>NCT02344095</DOCNO>
	<brief_summary>The investigator aim evaluate safety weekly paclitaxel oncothermia weekly cisplatin oncothermia patient recurrent persistent epithelial ovarian , fallopian tube primary peritoneal carcinoma . This trial randomize phase 1 trial . The investigator plan perform 1 year . In trial , total 12 patient recurrent persistent epithelial ovarian , fallopian tube primary peritoneal carcinoma randomly assign either paclitaxel cisplatin group ratio 1 1 . Paclitaxel group treat weekly paclitaxel oncothermia . Cisplatin group treat weekly cisplatin oncothermia . In group , limit toxicity evaluate treat 3 patient 4-cycles . Primary endpoint occurrence limit toxicity . Secondary endpoint response rate , progression-free survival , overall-survival , quality life , pain , fatigue compliance rate .</brief_summary>
	<brief_title>A Trial Weekly Paclitaxel With Oncothermia Weekly cisPlatin With Oncothermia Patients With Recurrent Persistent Ovarian Cancer</brief_title>
	<detailed_description>This trial randomize phase 1 trial . We plan perform 1 year . Subjects study patient diagnose recurrent persistent epithelial ovarian , fallopian tube primary peritoneal carcinoma . The number subject study 12 patient ( If patient assess , replace new patient ) . All subject randomly assign , treated weekly paclitaxel weekly cisplatin . In paclitaxel group , patient treat weekly paclitaxel 70mg/m2 ( IV ) day 1 , 8 , 15 interval 4 week . In cisplatin group , patient treat weekly cisplatin 40mg/m2 ( IV ) day 1 , 8 , 15 interval 4 week . Thermotherapy perform apply oncothermia ( EHY 2000 ) probe part body tumor locate deliver energy . It perform day 1 , 4 , 8 , 11 , 15 , 18 , 21 , 24 ( 8 time total every cycle ) . Oncothermia perform day earlier schedule day day later schedule day . It take 60 minute treat site oncothermia . Energy gradually increase 60W 140W . With tumor multiple site , oncothermia perform several time change site apply probe type probe . Oncothermia perform 60 minute per application . Patients recurrent persistent epithelial ovarian , fallopian tube primary peritoneal carcinoma randomly assign either paclitaxel cisplatin group ratio 1 1 . Paclitaxel group treat weekly paclitaxel oncothermia . Cisplatin group treat weekly cisplatin oncothermia . In group , limit toxicity evaluate treat 3 patient 4-cycles . In group limit toxicity occur rate equal le 1 patient , limit toxicity evaluate treat 3 additional patient 4-cycles . When limit toxicity occur rate equal le one six assessable patient , consider specific therapy safe enough used phase 2 trial . Primary endpoint occurrence limit toxicity . Secondary endpoint response rate , progression-free survival , overall-survival , quality life , toxicity , pain , fatigue compliance rate . Patients visit twice week 4-cycles complete progression disease confirm .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Recurrent persistent epithelial ovarian , fallopian tube primary peritoneal carcinoma ( At first diagnosis , pathologic finding confirm . ) Response assessment possible use radiologic test tumor markers The number chemotherapeutic regimens previously use ≤ 2 Adequate hematologic , hepatic , renal function ECOG performance status 0 2 Recurrent persistent epithelial ovarian , fallopian tube primary peritoneal carcinoma locate part body impossible deliver energy use oncothermia ( EHY 2000 ) probe Neurotoxicity ≥ grade 2 Pacemaker user Large metal material artificial joint keep body Recurrent persistent epithelial ovarian , fallopian tube primary peritoneal carcinoma locate part body get previously radiation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>recurrent , persistent</keyword>
</DOC>